Prurigo Nodularis (PN) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Prurigo Nodularis Emerging Therapy and TPP Insights

Thelansis's "Prurigo Nodularis (PN) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Prurigo Nodularis Overview

Prurigo nodularis (PN) is a chronic neuroimmune skin disorder characterized by intensely pruritic, firm nodules and an itch-scratch cycle that can cause excoriation, pain, sleep disturbance, and quality-of-life impairment. Its pathobiology involves interactions among sensory nerves, keratinocytes, and immune pathways, particularly IL-4/IL-13 and IL-31 signaling. Management is multimodal and may include topical corticosteroids, calcineurin inhibitors, phototherapy, and systemic therapy for extensive disease. Dupilumab, an IL-4 receptor alpha antagonist, and nemolizumab, an IL-31 receptor antagonist, are FDA-approved for adults with PN, demonstrating the value of targeted neuroimmune modulation. Current development is exploring additional cytokine, JAK and neural pathways to address inadequate response, treatment limitations, and disease heterogeneity. Key unmet needs include durable control of itch and lesions, treatment sequencing, and effective options for refractory disease globally.

Key Highlights

• In Germany, the prevalent Prurigo Nodularis (PN) population is projected to increase from 127,122 in 2025 to 129,438 by 2035.
• Prurigo Nodularis is a chronic inflammatory skin disease characterized by severe pruritus and nodular skin lesions.
• Persistent itching and recurrent disease significantly impair patients' quality of life.
• Significant unmet need remains for therapies that provide sustained itch relief and long-term disease control.

Market Overview

• The Germany Prurigo Nodularis market is projected to grow from $45M in 2025 to $95M by 2035.
• Market growth is driven by:
• Increasing adoption of targeted biologic therapies
• Improved diagnosis and growing disease awareness
• Future growth will depend on therapies capable of delivering durable symptom control and improved patient outcomes.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Trevi Therapeutics
• Incyte Corporation
• Sanofi
• Amgen
• Beijing InnoCare Pharma Tech Co., Ltd.
• Guangdong Hengrui Pharmaceutical Co., Ltd.
• Genentech, Inc.